NasdaqCM - Delayed Quote USD

ImmuCell Corporation (ICCC)

5.10 +0.06 (+1.19%)
At close: April 25 at 4:00 PM EDT
5.21 +0.11 (+2.16%)
After hours: April 25 at 5:50 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Michael F. Brigham President, CEO, Principal Financial Officer, Treasurer, Secretary & Director 395.24k -- 1961
Ms. Bobbi Jo Brockmann VP of Sales & Marketing and Director 323.52k -- 1977
Mr. A. Gustavo Scaffa Senior Director of Quality -- -- --
John W. Zinckgraf Director of Product Development -- -- --

ImmuCell Corporation

56 Evergreen Drive
Portland, ME 04103
United States
207 878 2770 https://immucell.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
74

Description

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Corporate Governance

ImmuCell Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024
ImmuCell Corporation Earnings Call

Related Tickers

PRTC PureTech Health plc
27.33
-5.27%
 
OKYO OKYO Pharma Limited
1.4467
+2.60%
 
NLSP NLS Pharmaceutics Ltd.
0.1324
+5.92%
 
MGTX MeiraGTx Holdings plc
4.7100
-3.09%
 
PASG Passage Bio, Inc.
1.2200
-1.61%
 
SLN Silence Therapeutics plc
21.62
-2.92%
 
LSTA Lisata Therapeutics, Inc.
2.6600
-3.97%
 
GLUE Monte Rosa Therapeutics, Inc.
5.45
-0.37%
 
PRTG Portage Biotech Inc.
0.2370
-9.78%
 
BCDA BioCardia, Inc.
0.3680
-3.03%